Objective To summarize the research progress of MRI in the assessment of rectal cancer before surgery. Methods Literatures about the recent studies on the research progress of MRI in the assessment of rectal cancer before surgery were reviewed according to the results searched from Pubmed, CNKI, and WanFang database. Results Preoperative staging, circumferential resection margin, and extramural vascular invasion were closely related to the prognosis of rectal cancer patients, MRI could provide a good assessment of preoperative staging, circumferential resection margin, and extramural vascular invasion for rectal cancer patients, but it still had some deficiencies which needed further studies. Conclusion Application of MRI in the assessment of preoperative staging, circumferential resection margin, and extramural vascular invasion before surgery, is conducive to the development of the most appropriate treatment options for patients with rectal cancer.
Lung cancer has a high morbidity and mortality, and invasion is one of the major factors that cause recurrence and death in lung cancer patients. Tumor-associated macrophages (TAMs) are cells that have the potential to secrete cytokines, growth hormones, inflammatory substrates, and protein hydrolases, which are associated with the growth, invasion and metastasis of tumors. In this article, we will explore the various chemicals that are manufactured to promote the invasion of lung cancer, as well as the numerous clinical therapeutic features that TAMs possess in the treatment of lung cancer. In addition, we look at the possibility that TAMs might be beneficial in the treatment of lung cancer. We have an innovative investigation of the huge variety of complex substances generated by TAMs, with the goal of determining whether or not the molecules under investigation have the potential to serve as new therapeutic targets. Throughout the whole of the presentation, a significant focus is placed on doing in-depth research to ascertain whether TAMs have the capability to reinforce as viable carriers for unique and creative medications. This not only provides novel concepts for the creation of new targeted therapies but also leads to the development of brand-new, cutting-edge methods for the manufacture of individualized medicines and drug carriers.
ObjectiveTo establish a model of portal hypertension with hypersplenism in SD rats by portal vein binding combined with splenic vein ligation. MethodsSixty healthy male SD rats were randomly divided into three groups: sham operation group （only laparotomy, n=20）, portal vein binding group (only binding, n=20), and portal vein binding combined with splenic vein ligation group (combined operation group, n=20). The counts of platelet, erythrocyte, and leukocyte were examined just before operation and once a week after operation for 7 weeks. Portal pressure, shortaxis, and longaxis diameter of spleen were examined just before operation and seven weeks after operation. At the seventh week, all the animals were sacrificed, spleen index and pathology changes of each group were examined. ResultsErythrocyte and platelet counts in combined operation group were significantly lower than those in the other two groups on the third week （Plt;0.05）, and there was no significant difference in leukocyte count among three groups （Pgt;0.05）. Compared with the preoperative value, portal pressure increased significantly on the seventh week in both portal vein binding group and combined operation group, and was higher than that in the sham operation group （Plt;0.05）. The two diameters of spleen also increased significantly in combined operation group on the seventh week （Plt;0.05）, and were larger than those in the other two groups （Plt;0.05）. The same result was found in spleen index （Plt;0.05）. Typical pathological changes of hypersplenism presented only in combined operation group on the seventh week after operation. ConclusionsPortal vein binding combined with splenic vein ligation can induce experimental secondary hypersplenism successfully. This procedure is simple and stable, and helpful to the scientific research.
目的 应用联合微创介入方法治疗中晚期肝癌并探讨其疗效。方法 我院自1998年4月至2008年11月期间采用联合介入治疗的方法，即行经皮股动脉插管肝动脉化疗栓塞术，同期行B超引导下经皮穿刺瘤内乙醇注射(PEI)治疗中晚期肝癌175例。结果 左肝动脉行肝动脉化疗栓塞7例，右肝动脉行125例，单行化疗而未栓塞43例； 175例均行B超引导下PEI。随访6～28个月，平均19.3个月，死亡15例，其中8例死于肝功能衰竭，7例死于上消化道大出血伴肝癌广泛转移。29例存活6～12个月； 146例存活13～28个月，其中27例存活已超过26个月。结论 对于不能切除的中晚期肝癌采用联合介入治疗，因其具有操作简单、疗效可靠、经济、安全等优点，值得临床推广应用。
ObjectiveTo explore the variation tendency of hospital infection and the antibacterial usage between 2011 and 2012,analyze the factors for hospitalization infection,and instruct on taking effective intervention measures,in order to reduce the rate of hospital infection,and thus to provide a scientific basis for the prevention and control of hospital infection. MethodsAll patients hospitalized in our hospital from 00:00 to 24:00 between September 21,2011 and August 16,2012 were investigated.By using the method of combined clinical investigation and case study,we asked the patients to fill the case questionnaires standardly,and analyzed the hospital infection cases on the survey day. ResultsA total of 1165 hospitalized patients were investigated from the year 2011 to 2012,and the actual check rate was 100%.A total of 46 cases of hospital infection occurred in 39 patients.The prevalence rate of hospital infection was 3.88% in 2011 and 2.80% in 2012.High rate hospital infections occurred in the Department of Neurosurgery which was 27.27% and Cardiothoracic surgery which was 16.67% in 2011.In 2012,the departments included ICU which was 28.57% and Internal Cardiovascular Medicine which was 9.09%.The main infection sites were respiratory tract,followed by urinary tract and superficial incisions.The usage rates of antibiotics were 63.07% and 40.56% respectively in the two years.There were significant difference in antibiotic use rate between the two years (P<0.01). ConclusionThe focus of future work is to strengthen the management of respiratory tract,urinary tract and surgical site infections,and to use antimicrobial drugs reasonably,in order to reduce hospital infection effectively.
The objective of this study was to determine the visco-hyperelastic constitutive law of brain tissue under dynamic impacts. A method combined by finite element simulations and optimization algorithm was employed for the determination of material variables. Firstly, finite element simulations of brain tissue dynamic uniaxial tension, with a maximum stretch rate of 1.3 and strain rates of 30 s–1 and 90 s–1, were developed referring to experimental data. Then, fitting errors between the engineering stress-strain curves predicted by simulations and experimental average curves were assigned as objective functions, and the multi-objective genetic algorithm was employed for the optimation solution. The results demonstrate that the brain tissue finite element models assigned with the novel obtained visco-hyperelastic material law could predict the brain tissue’s dynamic mechanical characteristic well at different loading rates. Meanwhile, the novel material law could also be applied in the human head finite element models for the improvement of the biofidelity under dynamic impact loadings.
The human gut microbiota regulates many host pathophysiological processes including metabolic, inflammatory, immune and cellular responses. In recent years, the incidence and mortality of lung cancer have increased rapidly, which is one of the biggest challenges in the field of cancer treatment today, especially in non-small cell lung cancer. Animal models and clinical studies have found that the gut microbiota of non-small cell lung cancer patients is significantly changed compared with the healthy people. The gut microbiota and metabolites can not only play a pro-cancer or tumor suppressor role by regulating immune, inflammatory responses and so on, but also be related with radiotherapy and chemotherapy of non-small cell lung cancer and the resistance of immunotherapy. Therefore, gut microbiota and related metabolites can be both potential markers for early diagnosis and prognosis in patients with non-small cell lung cancer and novel therapeutic targets for targeted drugs. This study will review the latest research progress of effect of gut microbiota on non-small cell lung cancer, and provide a new diagnosis and treatment ideas for non-small cell lung cancer.